PRESS RELEASE published on 11/20/2024 at 07:00, 1 year ago Inside Information / Other news releases Innate Pharma releases its 2025 financial calendar including key publication dates for financial statements and shareholder meetings Financial Statements Investors Financial Calendar 2025 Innate Pharma
BRIEF published on 11/08/2024 at 07:05, 1 year ago Innate Pharma présente ses innovations en oncologie au SITC 2024 Immunothérapie Innate Pharma NK Cell Engager SITC 2024 Conjugué Anticorps-médicament
BRIEF published on 11/08/2024 at 07:05, 1 year ago Innate Pharma presents its innovations in oncology at SITC 2024 Immunotherapy Innate Pharma SITC 2024 NK Cell Engage Antibody-drug Conjugate
PRESS RELEASE published on 11/08/2024 at 07:00, 1 year ago Informations privilégiées / Autres communiqués Annonce de Innate Pharma sur les présentations de données de son portefeuille innovant en oncologie sélectionnées pour le congrès annuel du SITC 2024 Immunothérapie Oncologie ADC Innate Pharma SITC 2024
PRESS RELEASE published on 11/08/2024 at 07:00, 1 year ago Inside Information / Other news releases Innate Pharma announces new preclinical data on IPH6501 and IPH4502 to be presented at SITC Annual Meeting 2024. Advances in immunotherapy reflected in drug development progress Drug Development Preclinical Data Immunotherapy Innate Pharma SITC Annual Meeting 2024
PRESS RELEASE published on 09/12/2024 at 13:09, 1 year 2 months ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
BRIEF published on 06/17/2024 at 07:05, 1 year 5 months ago Innate Pharma dévoile des résultats prometteurs pour le SAR443579/IPH6101 dans des cancers du sang Sanofi Innate Pharma SAR443579 Leucémie Cancer Du Sang
BRIEF published on 06/17/2024 at 07:05, 1 year 5 months ago Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers Sanofi Innate Pharma SAR443579 Leukemia Blood Cancer
PRESS RELEASE published on 06/17/2024 at 07:00, 1 year 5 months ago Informations privilégiées / Autres communiqués Innate Pharma présente de nouveaux résultats sur l'essai de phase 1/2 mené par Sanofi évaluant le NK Cell Engager SAR443579/IPH6101 dans divers cancers du sang lors du congrès annuel de l'EHA 2024 Étude De Phase 1/2 Innate Pharma NK Cell Engager SAR443579/IPH6101 Cancers Du Sang
PRESS RELEASE published on 06/17/2024 at 07:00, 1 year 5 months ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
Published on 12/05/2025 at 02:35, 6 hours 47 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 8 hours 22 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 17 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 22 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 09:05, 17 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 37 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 37 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 39 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 15 hours 7 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 15 hours 22 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
